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Background: The RET tyrosine kinase receptor has emerged as a target in thyroid and endocrine resistant breast
cancer. We previously reported the synthesis of kinase inhibitors with potent activity against RET. Herein, we have
further investigated the effect of the lead compound SPP86 on RET mediated signaling and proliferation. Based on
these observations, we hypothesized that SPP86 may be useful for studying the cellular activity of RET.
Methods: We compared the effects of SPP86 on RET-induced signaling and proliferation in thyroid cancer cell lines
expressing RET-PTC1 (TPC1), or the activating mutations BRAFV600E (8505C) and RASG13R (C643). The effect of SPP86
on RET- induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK pathway signaling and cell proliferation in
MCF7 breast cancer cells was also investigated.
Results: SPP86 inhibited MAPK signaling and proliferation in RET/PTC1 expressing TPC1 but not 8505C or C643 cells.
In TPC1 cells, the inhibition of RET phosphorylation required co-exposure to SPP86 and the focal adhesion kinase (FAK)
inhibitor PF573228. In MCF7 cells, SPP86 inhibited RET- induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK
signaling and estrogen receptorα (ERα) phosphorylation, and inhibited proliferation to a similar degree as tamoxifen.
Interestingly, SPP86 and PF573228 inhibited RET/PTC1 and GDNF- RET induced activation of Akt and MAPK signaling
to a similar degree.
Conclusion: SPP86 selectively inhibits RET downstream signaling in RET/PTC1 but not BRAFV600E or RASG13R expressing
cells, indicating that downstream kinases were not affected. SPP86 also inhibited RET signaling in MCF7 breast cancer
cells. Additionally, RET- FAK crosstalk may play a key role in facilitating PTC1/RET and GDNF- RET induced activation of
Akt and MAPK signaling in TPC1 and MCF7 cells.
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The REarranged during Transfection (RET) receptor
tyrosine kinase (RTK) regulates key aspects of cellular
proliferation and survival by regulating the activity of
the mitogen- activated protein kinase (MAPK) and
PI3K/Akt signaling pathways [1,2]. RET also interacts
directly with other kinases such as the epidermal growth
factor receptor (EGFR) and hepatocyte growth factor
receptor (MET) and the focal adhesion kinase (FAK)
[1,3,4]. Deregulated RET activity has been identified as a
causative factor in the development, progression and
response to therapy of thyroid carcinoma. Elevated RET
expression has been associated with the development of* Correspondence: John.P.Alao@cmb.gu.se
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unless otherwise stated.endocrine resistance in human breast cancer [5,6]. A
number of studies have also identified RET fusion
proteins in lung adenocarcinomas [7-9]. Together, these
findings suggest that RET presents an attractive thera-
peutic target for the treatment of certain cancer subsets.
Despite recent advances, the precise roles of RET in
mediating cell proliferation, survival, migration, and
resistance to therapy remain unclear. The activity of
RTKs and their downstream targets is regulated by a
complex array of kinase interactions and feedback loops
[10,11]. Hence, directly targeting RAF kinases can lead
to transactivation of RAF dimers, increased activation of
MAPK signaling and tumor progression [11,12]. Further
research on the role of RET in regulating these activities
is thus important for the development of proper thera-
peutic strategies. Chemical inhibitors can prove usefuld. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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by complementing other model systems such as those
employing protein over-expression, chemical- induced
dimerization (CID) and siRNA technology [13,14]. For
instance, signaling events often occur in the range of
seconds and the ability to rapidly inhibit signaling can
be extremely useful for investigations of this nature.
Studies on structure- activity relationships using cell line
models can also provide insights that direct the design
and synthesis of novel kinase inhibitors. Unfortunately,
the usefulness of kinase inhibitors in particular, is limited
by their relative lack of selectivity. It can thus be difficult
to specifically link observed cellular responses to inhib-
ition of the desired target protein. Furthermore, the off
target effects of kinase inhibitors can result in undesir-
able side effects if and when they are employed clinically
[11,15,16]. Several kinase inhibitors with differential
selectivity towards RET have been reported to date.
Almost without exception, these inhibitors target several
other kinases apart from RET with equal or higher affin-
ity and accordingly induce a diverse range of effects in
different cell lines (Table 1) [17-19]. Several of these
compounds have entered clinical trials with promising
results [1]. While multi-kinase inhibition might be bene-
ficial for cancer treatments, it is also associated with a
higher incidence of side effects. The inhibition of vascular
endothelial growth factor receptor 2 (VEGFR2), in
particular, has been associated with undesirable side
effects [17]. The inhibition of multiple kinases by an
inhibitor can severely restrict its usefulness as a chemical
tool [13,20,21]. For instance, RET has been shown to func-
tionally interact with several other kinases such as EGFR,
FAK, and MET [3,4,22-24]. Furthermore, BRAF andTable 1 Kinase inhibitors with inhibitory activity towards RET
Inhibitor Targets (IC50)
PP1 Lyc (5nM), fyn (6 nM), Src (170 nM), Csk (520 nM), CK
RPI-1 MET (7.5 μM), RET (170 nM),
PHA-739358
(Danusertib)
Aurora kinase A/B/C (13 nM/79 nM/61 nM), BCR-ABL
TG101209 JAK2 (6 nM), FLT3 (25 nM), RET (17 nM)
SU 5416 (Semaxanib) RET (944 nM), VEGFR (nM), KIT, MET, FLT3
SU11248 (Sunitinib) RET (224 nM), VEGFR2 (4 nM), FLT3 (8–14 nM), KIT (1
XL184 (Cabozantinib) VEGFR2 (0.035 nM), MET (1.3 nM), RET (4 nM), KIT (4.6
TIE2 (14.3 nM), AXL (7 nM)
BAY 43–9006
(Sorafenib)
RET (5.9- 47 nM), BRAF (25 nM), VEGFR1/2/3 (20–90 n
KIT (68 nM)
ZD6474 (Vandetanib) RET (130 nM), VEGFR2 (40 nM), VEGFR3 (110 nM), EG
AP24534 (Ponatinib) RET (7 nM), ABL (0.4 nM), Lyn (0.2 nM), FLT3 (13 nM)
VEGFR2 (2 nM)
NVP-AST487 RET (880 nM), KDR (170 nM), FLT-4 (790 nM), KIT (500
NVP-BBT594 RET (~100 nM), JAK2 (1 nM), Tyk2 (1 nM), JAK3 (5 nM
ZAP70 (200 nM), FGFR2 (940 nM)p38MAPK are downstream targets of RET [5]. Kinase
inhibitors that simultaneously inhibit RET and its down-
stream targets (or kinases it interacts with) will produce
results in cell based assays that are difficult to interpret
[13,20,21]. The continued design and synthesis of novel
inhibitors with selective activity towards RET is thus
important [17,18,25].
We recently reported the design and synthesis of a
small library of selective, cell permeable kinase inhibitors
with activity against RET [45]. The lead compound
(SPP86) [45] has previously been shown by us to exhibit
high selectivity towards RET and potently inhibits its
activity in vitro. Although SPP86 shows high selectivity
for RET in vitro, it also inhibited EPHA1, FGFR1,
FGFR2, FLT4, LCK, YES at low doses (<0.4 μM) under
these conditions. As such, its selectivity profile differs
from that of other kinase inhibitors reported to inhibit
RET activity. Furthermore SPP86 is cell permeable and
inhibits RET signaling in human cancer cell lines at low
concentrations [45]. Our observations suggest that
SPP86 may be a useful chemical tool for studies on RET
signaling in cancer models. In this study, we further
investigated the utility of SPP86 as a chemical tool for
studies on RET signaling in human cancer cell lines.
Based on its selectivity profile, we predicted that low
doses of SPP86 would exert little or no effect on the
signaling and proliferation of cell lines that do not
depend on RET for these activities. We compared the
effect of SPP86 on MAPK kinase signaling and prolifera-
tion in RET/PTC1 (TPC1), BRAFV600E (8505C) and
RASG13R (C643) expressing thyroid cancer cell lines.
Widening the scope beyond cancer types traditionally
considered to be RET-driven, we also investigated theReference
1δ (1060 nM), p38MAPK (640 nM), RET (80 nM) [20,26,27]
[28-30]
(25 nM), RET(31 nM), FGFR1 (47 nM) [31]
[32]
[33,34]
–10 nM), PDGFRβ (39 nM), CSF1R (50–100 nM) [35]
nM), FLT-1/3/4 (12 nM/ 11.3 nM /6 nM, 14.3 nM), [36]
M), FLT3 (33 nM), p38MAPK (38 nM), PDGFRβ (57 nM), [35,37]
FR (500 nM) [38,39]
, KIT (13 nM), FGFR1 (2 nM), PDGFRα (1 nM), Src (5.4 nM), [40,41]
nM), FLT-3 (520 nM), ABL (20 nM) [42]
), JAK1 (15 nM), FAK (100 nM), IRK-3P (200 nM), [43,44]
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and proliferation in MCF7 breast cancer cells.
Methods
Reagents
The RET inhibitor SPP86 was synthesized by a literature
procedure [45]. Stock solutions of SPP86 (10 mM) in
DMSO were stored at 4°C and diluted just prior to use.
17-β estradiol (E2), 4- hydroxy tamoxifen (4-OHT) and
insulin were obtained from Sigma-Aldrich (Stockholm,
Sweden) dissolved in ethanol and stored at 4°C. PF-
573228 was from Tocris Bioscience (Bristol, United
Kingdom), dissolved in DMSO and stored at −20°C.
ICI182,780 was from Tocris Bioscience dissolved in etha-
nol and stored at −20°C. Sorafenib (BAY43-9006) was
obtained from AH Diagnostics AB (Skärholmen, Sweden)
and stock solutions in DMSO were stored at -20°C.
Recombinant human GDNF was obtained from R&D
systems (Abingdon, United Kingdom) and was reconsti-
tuted and stored according to the supplier’s instructions.
Cell culture
MCF7 breast cancer cells from in-house stocks were
maintained in Dulbecco’s modified eagle medium (DMEM)
supplemented with heat inactivated 10% (v/v) fetal bovine
serum (FBS), 2 mM L-glutamine, 100 units/ml penicillin
and 100 μg/ml streptomycin at 37°C in humidified 5%
CO2. 8505C, C643 and TPC1 thyroid cancer cell lines were
maintained in RPMI 1640 under similar conditions. The
8505C and C643 cells as well as the TPC1 cells were kind
gifts from P. Soares and L. Mologni respectively. For estro-
gen and serum deprivation, MCF7 cells were cultured for
3 days in phenol red free RPMI 1640 supplemented with
10% (v/v) charcoal stripped FBS followed by 24 h in the
same medium containing 1% (v/v) charcoal stripped FBS.
For 4-OHT response assays, MCF7 cells were cultured for
3 days in phenol red free RPMI 1640 supplemented with
10% (v/v) charcoal stripped FBS followed by 24 h in the
same medium containing 0.1% (v/v) charcoal stripped FBS.
Antibodies
Antibodies directed against RET (C31B4), Akt1 (2H10),
phospho-Ser473 Akt (193H12), p70 S6 Kinase, phospho-
Thr389 p70 S6 Kinase (108D2), p44/42 MAPK (ERK1/2)
(137 F5), phospho-Thr202/Tyr204 p44/42 MAPK (ERK1/2)
(197G2), phospho- Src Tyr416, (D49G4), Src (36D10) and
phospho-Ser167 (D1A3) ERα were from Cell Signaling
Technologies (Bionordika (Sweden) AB, Stockholm,
Sweden). Antibodies directed against β- catenin (B-9),
phospho- Tyr654 β- catenin (1B11), cyclin D1 (DCS-6),
PARP-1/2 (H-250), RET (C-19), phospho-Tyr1062 RET,
PARP (H-250) and Sp1 (E3) were from Santa Cruz
Biotechnology (Heidelberg, Germany) and against ERα
(6 F11) from Leica Microsystems AB (Kista, Sweden).Antibodies directed against phospho- Tyr576 FAK and
FAK were from Invitrogen (Lidingö, Sweden). Mono-
clonal antibodies directed against actin and α-tubulin
were from Sigma-Aldrich.
Cell viability assays
For cell viability assays, cells were seeded in 96-well plates
at optimal cell density to ensure exponential growth for
the duration of the assay. After 24 h preincubation,
growth medium was replaced with experimental medium
containing the appropriate drug concentrations or vehicle
controls (0.1% or 1.0% v/v DMSO). After 48 h incubation,
cell viability was measured using PrestoBlue™ Cell Viability
Reagent (Invitrogen) according to the manufacturer’s
instructions. Fluorescence was measured at the excitation
and emission peaks for resorufin (544 and 590 nm
respectively). Results were expressed as the mean ± S.E.
for six replicates as a percentage of vehicle control (taken
as 100%). Experiments were performed independently at
least three times. Statistical analyses were performed using
a two tailed Student’s t test. P <0.05 was considered to be
statistically significant.
Immunoblotting
Cells treated as indicated were washed with ice-cold phos-
phate buffered saline (PBS) and lysed directly in ice-cold
HEPES buffer [50 mM HEPES (pH 7.5), 10 mM NaCl,
5 mM MgCl2, 1 mM EDTA, 10% (v/v) glycerol, 1% (v/v)
Triton X-100 and a cocktail of protease inhibitors (Roche
Diagnostics Scandinavia AB, Bromma, Sweden)] at 4°C for
30 min with gentle agitation. The supernatants were either
analyzed immediately or stored at -80°C. Equivalent
amounts of protein (20 – 50 μg) from total cell lysates
were resolved by SDS-PAGE and transferred onto ‘nitro-
cellulose membranes. Membranes were blocked in block-
ing buffer [5% (w/v) nonfat dried milk, 150 mM NaCl,
10 mM Tris (pH 8.0) and 0.05% (v/v) Tween 20]. Proteins
were detected by incubation with primary antibodies at
appropriate dilutions in blocking buffer overnight at 4°C.
Blots were then incubated at room temperature with
horseradish peroxidase-conjugated secondary antibody.
Bands were visualized by enhanced chemiluminescence
(Supersignal West Pico; Pierce, Nordic Biolabs AB, Täby,
Sweden) followed by exposure to autoradiography film
(General Electric Bio-Sciences, Uppsala, Sweden). Anti-
bodies directed against PARP [46] or tubulin were used to
monitor gel loading. Cytoplasmic and nuclear extracts
were prepared using an NE-PER extraction kit (Thermo
Scientific Inc., Rockford, IL, USA) according to the manu-
facturer’s instructions.
Immunofluorescence microscopy
Cells were grown on sterile glass coverslips in 6-well
plates to 80% confluence in media before being washed
Figure 1 (See legend on next page.)
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Figure 1 SPP86 selectively inhibits RET- induced ERK1/2 phosphorylation in thyroid cancer cell lines. (A) TPC1 cells were cultured
overnight in media containing 0.1% FBS and exposed to the indicated concentrations of sorafenib or SPP86 for 90 min in similar media. Total
lysates were resolved by SDS-PAGE and probed with antibodies directed against phosphorylated (Thr202/Tyr204) and total ERK1/2. Monoclonal
antibodies directed against actin were used to monitor gel loading. (B) 8505C cells expressing mutant BRAFV600E and (C) C643 expressing mutant
RASG13R were treated as in A. (D) TPC1 cells were treated as in C. Total lysates were resolved by SDS-PAGE and probed with antibodies directed
against phosphorylated (Tyr1062), total RET, phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2. Monoclonal antibodies directed against
tubulin were used to monitor gel loading. (E) TPC1 cells were cultured in media containing 0.1% FBS overnight and then exposed to the indicated
concentrations of SPP86 for 20 h under the same conditions. Total lysates were resolved by SDS- PAGE and membranes were probed with the
indicated antibodies. Monoclonal antibodies directed against PARP were used to monitor gel loading. (F) TPC1 cells cultured in media containing
0.1% FBS were exposed to the indicated concentration of SPP86 for 90 min. Total cell lysates were resolved by SDS- PAGE and probed with antibodies
directed against phosphorylated and total RET or phosphorylated and total ERK1/2. PARP was used instead of actin or tubulin to monitor gel loading,
to enable the simultaneous detection of Akt and ERK1/2 on the membrane. (G) 8505C and C643 cells were cultured overnight in media containing
0.1% FBS. Cells were exposed to the indicated concentrations of SPP86 for 20 h. Lysates were probed with antibodies directed against the
indicated proteins.
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PBS at room temperature for 10 minutes. Coverslips were
washed twice in PBS and permeabilized in 0.2% Triton
X100/PBS for 15 minutes. Following another three washes
in PBS, coverslips were blocked in 3% bovine serum albu-
min (BSA)/PBS at room temperature for 30 min. Mono-
clonal antibodies to β- catenin (B-9) were applied in 3%
BSA/PBS overnight. Cells were then washed 3 times in
PBS, and incubated with a fluorescein isothiocyanate
(FITC) -conjugated bovine or goat anti-mouse secondary
antibody (1:200) (Santa Cruz Biotechnology) at room
temperature for 1 h. After a final three washes, coverslips
were mounted on glass slides with Vectorshield containing
4′,6′-diamidino-2-phenylindole (DAPI) (Vector Labora-
tories Ltd., Peterborough, United Kingdom). Alternatively,
cells were stained with FITC- conjugated phalloidin.
Images were obtained with a Zeiss AxioCam on a Zeiss
Axioplan 2 microscope with a 100 × objective using the
appropriate filter sets.
Results
We investigated the effect of SPP86 on ERK1/2 phosphor-
ylation in thyroid cancer derived cell lines expressing the
RET/PTC1 rearrangement (TPC1), BRAFV600E (8505C) or
RASG13R (C643) mutations [47,48]. These mutations have
previously been shown to induce constitutive activation of
the MAPK signaling pathway in these cell lines [47-49].
Since TPC1 but not 8505C and C643 cells depend
predominantly on RET/PTC1 signaling for proliferation,
we hypothesized that SPP86 should only inhibit the prolif-
eration of the former. Sorafenib, which inhibits both RET
and RAF family kinases, was used as an internal control in
these experiments.
SPP86 inhibits MAPK pathway activation in RET/PTC1
expressing cell lines
As previously reported [45], SPP86 effectively inhibits
ERK1/2 phosphorylation in TPC1 cells expressing the
RET/PTC1 rearrangement at a concentration of 1 μM(Figure 1A). In contrast, SPP86 had no effect on ERK1/2
phosphorylation in 8505C or C643 cells (Figure 1B and C).
Sorafenib, which targets both RET and RAF kinases, effect-
ively inhibited ERK1/2 phosphorylation in TPC1 cells at a
concentration of 0.1 μM (Figure 1A). Sorafenib (10 μM)
also inhibited ERK1/2 phosphorylation in 8505C cells, and
to a lesser extent in C643 cells consistent with previous
reports [49] (Figure 1B and C). The differential sensitivity
of 8505C and C643 cells to SPP86 and sorafenib likely re-
sults from the latter’s effect on RAF signaling [49]. Interest-
ingly, SPP86 induced only modest inhibition of RET/PTC1
phosphorylation Tyr1062 at a concentration of 1 μM
(Figure 1D). Complete inhibition required 10 μM of SPP86
(Figure 1D). Thus, the ability of SPP86 to abolish ERK1/2
phosphorylation at 1 μM does not strictly correlate with its
inhibition of RET phosphorylation. Similar observations
have previously been reported with the RET inhibitor
RPI-1 [28]. SPP86 also inhibited Akt phosphorylation on
Ser473 at a concentration of 1.0 μM (Figure 1E and F).
Prolonged exposure (20 h) to 0.5- 1 μM SPP86 was also as-
sociated with a decline in cyclin D1 levels in this cell line
(Figure 1E). In contrast, prolonged exposure to SPP86 did
not affect ERK1/2 phosphorylation or cyclin D1 expression
in 8505C and C643 cells (Figure 1G). We noted however,
that prolonged exposure to SPP86 (0.5- 1.0 μM) was asso-
ciated with a decrease in Akt Ser473 phosphorylation in
C643 in cells (Figure 1G). C643 cells express wild type
RET [47]. SPP86 may thus inhibit RET- mediated Akt
activation in this cell line. These results demonstrate that
unlike sorafenib, SPP86 appears to selectively inhibit RET/
PTC1- activated MAPK signaling in these cell lines.
We next investigated if FAK could maintain RET phos-
phorylation on Tyr1062 despite the inhibition of RET
autophosphorylation by SPP86 [24]. Exposure to 2.5 μM
of the FAK inhibitor PF573228 [50] alone, did not inhibit
RET phosphorylation in TPC1 cells (Figure 2A). In
contrast, exposure to 2.5 μM of the FAK inhibitor
PF573228 in combination with 1 μM SPP86 was sufficient
to inhibit RET phosphorylation on Tyr1062 (Figure 2A).
Figure 2 SPP86- mediated RET inhibition does not abolish its phosphorylation TPC1 cells. (A) TPC1 cells were cultured overnight in media
containing 0.1% FBS and exposed to 2.5 μM PF573228 and/or 1 μM SPP86 for 90 min in similar media. Total lysates were resolved by SDS-PAGE
and probed with antibodies directed against phosphorylated (Tyr1062) and total RET. Actin was used to monitor gel loading. (B- D) Total lysates
were resolved by SDS-PAGE and probed with antibodies directed against the indicated proteins. Tubulin was used to monitor gel loading. (E)
TPCI cells were grown in media containing 0.1% FBS and the left untreated or cultured in the presence of 2.5 μM PF573228 and/or 1 μM SPP86
for 72 h. Viability was expressed as a percentage of the untreated control population. The data in each panel represent the mean of 3 experiments ± S. E.;
*p <0.01 treated vs. untreated for each series.
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ERK1/2 phosphorylation to a similar degree (Figure 2B
and C). Exposure to PF573288 but not SPP86 was associ-
ated with a reduction of FAK Tyr576 phosphorylation
(Figure 2B). Neither PF273228 nor SPP86 suppressed Src
phosphorylation (Figure 2D). SPP86 inhibited TPC1 cell
proliferation more effectively than PF573228 (49% prolif-
eration vs. 77%) but no additive effect was observed
following co-exposure to both drugs (Figure 2E).
Our observations strongly suggested that SPP86 would
selectively inhibit RET- induced proliferation. We thuscompared the effect of sorafenib and SPP86 on the
proliferation of TPC1, 8505C and C643 cells in media
containing 0.1% serum (i.e. low culture conditions).
Under these conditions, signaling pathway activation is
predominantly under the control of the respective onco-
genes expressed by these cell lines. C643 and TPC1 cells
showed marked differential sensitivity to SPP86 (IC50,
61.5 vs 1.5 μM for C643 and TPC1 cells respectively)
(Figure 3A). In contrast, 8505C cells grew poorly under
low serum conditions (data not shown), but their prolif-
eration was enhanced when exposed to doses of SPP86
Figure 3 SPP86 selectively inhibits RET- mediated proliferation in thyroid cancer cell lines. (A) TPC1 cells expressing RET/PTC1, 8505C cells
expressing mutant BRAFV600E and C643 expressing mutant RASG13R were cultured in medium containing 0.1% FBS in the presence of increasing
doses of sorafenib or SPP86 for 72 h. Viability was expressed as a percentage of the untreated control population. The data in each panel
represent the mean of at least 3 experiments ± S. E.; *p <0.05 for 8505C cells at 1–10 μM and C643 cells at 10 μM SPP86 vs. control, **p <0.0001
for TPC1 cells at 0.1- 10 μM SPP86 vs. control. (B) TPC1, 8505C and C643 cells were exposed to increasing concentrations of sorafenib in media
containing 0.1% FBS for 72 h. Viability was expressed as a percentage of the untreated control population. The data in each panel represent the
mean of 3 experiments ± S. E. for C643 and 8505C cells and the mean of 2 experiments ± S. E. for TCP1 cells; *p <0.05 for 0.1- 1.0 μM for TCP1
cells, 1.0 μM for C643 cells.
Alao et al. BMC Cancer 2014, 14:853 Page 7 of 13
http://www.biomedcentral.com/1471-2407/14/853from 1–10 μM (Figure 3A). Under similar conditions,
the IC50 values for sorafenib were 3.1 μM, 0.28 μM, and
33.3 μM for C643, TPC1 and 8505C cells respectively
(Figure 3B). In general, low doses of SPP86 do not in-
hibit the activity of signaling proteins downstream of
RET or other kinases that directly interact with it [45].
SPP86 thus selectively inhibited the proliferation of
TPC1 cells dependent on oncogenic RET but not 8505C
and C643 cells respectively dependent on oncogenic
BRAF and RAS.
SPP86 inhibits RET signaling in ERα positive breast
cancer cells
In addition to its role in thyroid cancers, RET has been
shown to functionally interact with ERα in human breast
cancer cell lines [5,6,51,52]. We thus evaluated the utility
of using SPP86 to interrogate RET signaling in MCF7
breast cancer cells. Firstly, we studied the effect of
SPP86 on RET- mediated ERα phosphorylation on serine
residue 167 (Ser167). Estrogen deprived and serum
starved MCF7 cells were exposed to 10 ng/ml GDNF in
the absence or presence of increasing does of SPP86. In
these experiments, SPP86 effectively inhibited GDNF/
RET- induced ERα phosphorylation at a concentration of
0.1 μM (Figure 4A). Higher concentrations of SPP86,
1–10 μM, reduced ERα phosphorylation even below base-
line levels. In addition, exposure of MCF7 cells to SPP86
was associated with a moderate decrease in ERα levels in
these experiments (Figure 4A) We next investigated theeffect of SPP86 on RET- mediated activation of these
pathways in MCF7 cells. SPP86 inhibited GDNF/ RET- in-
duced phosphorylation of Akt and its downstream signal-
ing at concentrations as low as 0.1 μM (Figure 4B). We
noted that SPP86 inhibited phosphorylation of Akt more
effectively than that of its downstream target p70S6K at
this concentration. Similarly, SPP86 inhibited Akt phos-
phorylation at markedly lower concentrations than those
required to inhibit MAPK phosphorylation (0.1 vs.
1.0 μM) (Figure 4B). SPP86 effectively inhibited GDNF-
induced RET phosphorylation Tyr1062 at a concentration
of 1.0 μM. In contrast, FAK inhibition with PF573228 only
moderately inhibited RET phosphorylation. Co- exposure
to PF573228 and SPP86 however, exerted an additive
inhibitory effect on RET phosphorylation (Figure 4C).
Both PF573228 and SPP86 inhibited GDNF- induced
ERK1/2 and Akt phosphorylation (Figure 4C and
Additional file 1A). Prolonged exposure of MCF7 cells to
SPP86 also lead to the suppression of cyclin D1 expression
(Figure 4D). We next compared the effects of sorafenib
and SPP86 on PI3K/Akt and MAPK pathway signaling,
with a view to discriminate the direct effects of RET inhib-
ition from those of a combined inhibition of RET and
RAF. In these experiments, estrogen deprived and serum
starved MCF7 cells were exposed to 10 ng/ml GDNF
alone or in the presence of either sorafenib or SPP86.
Analyses of the relative levels of phosphorylated Akt and
ERK1/2 demonstrated that both compounds effectively
block GDNF- induced RET signaling at concentrations as
Figure 4 (See legend on next page.)
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Figure 4 SPP86 inhibits RET- induced ERα phosphorylation and proliferation in MCF7 cells. (A) Estrogen- deprived and serum starved
MCF7 cells were exposed to the indicated concentrations of SPP86 for 30 min. The cells were then exposed to 10 ng/ml GDNF for another
30 min. Total lysates were resolved by SDS-PAGE and probed with antibodies directed against phospho- Ser167 and total ERα. Actin was used as
a loading control. (B) Estrogen- deprived and serum starved MCF7 cells were pretreated with the indicated concentrations of SPP86 for 30 min
and then exposed to 10 ng/ml of GDNF for a further 45 min. Total lysates were probed with the indicated antibodies. (C) MCF7 cells were grown
in media growing 1.0% FBS overnight, pretreated with 2.5 μM PF573228 and/or 1 μM SPP86 for 40 min and then exposed to 10 ng/ml of GDNF
for a further 20 min in similar media. Total lysates were resolved by SDS-PAGE and probed with antibodies directed against phosphorylated
(Tyr1062), total RET, phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2. Antibodies directed against tubulin were used to monitor gel
loading. (D) MCF7 breast cancer cells were cultured in media containing 1% FBS and then exposed to the indicated doses of SPP86 for 24 h. Total
lysates were probed with antibodies directed against cyclin D1 and tubulin. (E) Estrogen- deprived and serum starved MCF7 cells were
pretreated with the indicated concentrations of sorafenib or SPP86 and treated as in C. Antibodies directed against PARP were used to monitor
gel loading.
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nib inhibited Akt and ERK1/2 slightly more effectively
than SPP86 under these conditions (Figure 4E). These
differential effects on PI3K/Akt and MAPK signaling may
result may stem from the fact that sorafenib and SPP86
target different kinases at low concentrations. The
enhanced inhibition of MAPK signaling observed with
sorafenib may also result from the fact that it targets both
RET and RAF family kinases [37,45].
Since these observations suggested that SPP86 disrupts
ERα- RET crosstalk, we investigated the effect of SPP86
on the proliferation of MCF7 cells. Estrogen deprived
and serum starved cells were cultured in the presence of
1 ng/ml β- estradiol (E2) or 10 ng/ml GDNF alone and
in combination in the presence of 1 μM SPP86 for
7 days. SPP86 effectively inhibited E2 and/or GDNF-
induced proliferation (p <0.05) (Figure 5A). In contrast,
SPP86 did not inhibit proliferation when MCF7 cells
were co-exposed to 1 ng/ml E2 and 5 ng/insulin under
similar conditions (Figure 5B). We next compared the
effect of SPP86 and tamoxifen on the proliferation of
MCF7 cells. Estrogen deprived and serum starved cells
were cultured in the presence of 1 ng/ml β- estradiol
(E2) and 10 ng/ml GDNF with increasing doses of either
SPP86 or tamoxifen, in medium containing 1 ng/ml
β- estradiol (E2) and 10 ng/ml GDNF and incubated for
7 days. In these experiments, SPP86 and tamoxifen
inhibited proliferation to a similar degree with IC50
values of 1.0 and 1.4 μM respectively (Figure 5C).
Discussion
We have investigated the effect of SPP86, a novel small
molecule kinase inhibitor with selective activity towards
RET on cancer cell proliferation. SPP86 is cell perme-
able, potently inhibits RET activity in vitro and in vivo,
and exhibits a unique selectivity profile that differs from
previously reported inhibitors with activity towards this
kinase [45]. Deregulated RET activity has been associated
with the development, progression and/or resistance to
therapy of certain thyroid, breast and lung cancer
subtypes. Together, these studies have identified RET asa potentially important therapeutic target in these sub-
types of thyroid, breast and lung cancers [5-9]. Further
studies on RET will be required however, if effective
treatment regimens that target this kinase are to be
developed. Due to the rapidity of their actions, small
molecule tyrosine kinase inhibitors have been extremely
useful as chemical tools to study the physiological roles
of the pathways regulated by these enzymes [13,14,21].
Most if not all kinase inhibitors target more than one
kinase, leading to potentially confounding or erroneous
results when used to study cellular physiology. Several
small molecules with inhibitory activity towards RET
have been reported (Table 1). This problem can be par-
tially circumvented; by using two or more RET inhibi-
tors of dissimilar structure for studies of this nature
[13,20,21]. Given that no purely selective inhibitors of
RET exist, the continued characterization of small mole-
cules that target RET is desirable.
The differential selectivity profile of SPP86 suggested
it might be useful for studies on the cellular functions of
RET [45]. As previously reported for other RET inhibi-
tors [17-19,45], SPP86 inhibits RET mediated activation
of the PI3K/Akt and MAPK pathways at low doses
(0.1- 1 μM) in a cell line expressing oncogenic RET. In
this study, we have demonstrated that SPP86 selectively
inhibits this activity in a thyroid cancer cell line express-
ing RET/PTC1 but not in others with activating muta-
tions in BRAF (V600E) or Ras (G13R) which lie down
stream of RET. Furthermore, SPP86 selectively inhibited
the proliferation of the former at similar concentrations
while having little or no anti-proliferative effect on the
latter. Interestingly, SPP86 appears to enhance the pro-
liferation of 8505C cells which express constitutively
activated BRAFV600E under low serum conditions. It re-
mains to be determined, if this effect resulted directly
from the SPP86 mediated inhibition of RET.
Surprisingly, we observed only partial suppression of
RET phosphorylation on Tyr1062 following exposure to
low doses of SPP86. The near complete inhibition of Akt
and ERK1/2 by SPP86 at these doses, did not correlate
with inhibitory effects on RET phosphorylation. While
Figure 5 SPP86 inhibits RET- mediated proliferation. (A) Estrogen- deprived and serum starved MCF7 cells were left untreated or exposed to
1 ng/ml E2 and/or 10 ng/ml GDNF alone or in combination with 1 μg/ml SPP86 in phenol red- free media for 7 days. Proliferation was expressed
as fold increase in growth relative the untreated control population. The data represent the mean of 3 experiments ± S. E; *p <0.05 treated vs.
untreated for each series. (B) Estrogen- deprived and serum starved MCF7 cells were cultured in the presence of 1 nM E2 (estrogen) together
with 10 ng/ml of GDNF or 10 ng/ml insulin in the presence or absence of 1 μM SPP86 for 72 h. Proliferation was expressed as fold increase in
growth relative the untreated control population. The data represent the mean of 3 experiments ± S. E; *p <0.05. (C) Estrogen- deprived and
serum starved MCF7 cells exposed to increasing concentrations of SPP86 or 4-OHT in phenol red- free media containing 1 ng/ml E2 and 10 ng/ml
GDNF for 7 days. Viability was expressed as a percentage of the untreated control population. The data in each panel represent the mean of 3
experiments ± S. E.; *p <0.05, **p <0.0001.
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the reasons for this discrepancy remain unclear. FAK
has been shown to phosphorylate RET on Tyr1062 [24].
In our studies, FAK inhibition by PF573228 did affect
RET phosphorylation in TPC1 cells. Co-exposure to
PF273228 and SPP86 however, clearly inhibited RET
phosphorylation. SPP86 did not inhibit the activity of
FAK or its activating kinase Src in our studies. It is
possible, that FAK maintains the phosphorylation of
RET on Tyr1062 despite the inhibition of the latter’s
autophosphorylation by SPP86. Interestingly, exposure
to PF573228 or SPP86 inhibited Akt and ERK1/2 to a
similar degree in TPC1 cells. In contrast, low concentra-
tions of SPP86 clearly inhibited GDNF- induced RET au-
tophosphorylation in MCF7 cells. Exposure to PF573228alone only marginally inhibited GDNF- induced RET au-
tophosphorylation but enhanced the inhibitory effect of
SPP86 on this activity. PF573228 also inhibited RET-
dependent activation of Akt and ERK1/2 in MCF7 cells
to a similar degree as SPP86 (Figures 2 and 4). The pre-
cise role of FAK in regulating Akt and ERK1/2 phos-
phorylation as well as proliferation in MCF7 and TPC1
cells will require further studies. Our findings suggest
however, that RET autophosphorylation is insufficient to
activate downstream signaling and requires FAK activity.
TPC1 cells have also been shown to express FGFR1, a
target of SPP86 [53]. The role of FGFR1 in regulating
the aforementioned effects on cell signaling in TPC1
cells has not been reported. Therefore we cannot rule out
at present, that the inhibitory effect of SPP86 on TPC1
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FGFR1. RET/PTC1 is the main oncogenic driver in the
TPC1 cell line and activates both the Akt and MAPK
signaling pathways [54,55]. The observed selective effect
on RET driven proliferation therefore suggests that SPP86
predominantly inhibits signaling via this RTK.
The effectiveness of endocrine therapy for ERα positive
breast cancer is limited by the development of resistance.
Increased RTK signaling leads to estrogen independent ERα
activation and resistance to tamoxifen and aromatase inhib-
itors [56]. RET interacts functionally with ERα to promote
breast cancer cell proliferation and is frequently overex-
pressed in ERα positive breast cancer [5,51]. Furthermore,
overexpression of RET confers resistance to tamoxifen and
aromatase inhibitors [5,43]. RET mediated activation of the
PI3K/ Akt and MAPK pathways leads indirectly to the
phosphorylation and activation of ERα [5,57]. These studies
have identified RET as a potentially important target for the
treatment of endocrine resistant breast cancer. A small mol-
ecule inhibitor with inhibitory activity towards RET, NVP-
BBT594, has recently been shown to reverse resistance to
aromatase inhibitors in breast cancer cells [43]. The effect-
ive use of kinase inhibitors to study the roles of RET in cell
physiology will require the use of two or more structurally
similar inhibitors [13,21]. We have previously shown that
SPP86 inhibits GDNF- RET induced activation of the
MAPK pathway at low doses [45]. Herein, we have demon-
strated that SPP86 inhibits GDNF- RET induced phosphor-
ylation of ERα. Earlier studies have demonstrated that RET
indirectly induces ERα phosphorylation via activation of the
PI3K/Akt and MAPK pathways [5,57]. Interestingly, SPP86
appeared more effective at inhibiting the GDNF- RET in-
duced activation of the PI3K/Akt pathway than the MAPK
pathway (0.1 vs 1.0 μM). Furthermore, SPP86 inhibited
GDNF- RET induced ERα phosphorylation at concentra-
tions similar to those required to inhibit Akt phosphoryl-
ation. This is in agreement with previous findings showing
that inhibition of PI3K/Akt signaling is more effective at
blocking ERα phosphorylation that inhibition of the MAPK
pathway [5]. It is possible however, that SPP86 mediated in-
hibition of Src family kinases enhances its effect on Akt
phosphorylation [45,58]. ERα induces RET expression
which in turn enhances ERα phosphorylation and activation
in a positive feedback loop [5,6,51]. In our study, SPP86
inhibited the proliferation of MCF7 cells cultured in the
presence of estrogen and GDNF to the same degree as tam-
oxifen on a molar basis. In contrast, SPP86 did not inhibit
the proliferation of MCF7 cells cultured in the presence of
estrogen and insulin. Exposure to SPP86 was also associated
with a reduction in cyclin D1 levels. Cyclin D1 is a tran-
scriptional target of ERα and central regulator of cell cycle
progression in MCF7 cells [59,60]. SPP86 thus appears to
suppress MCF7 proliferation at least in part, by inhibiting
ERα- RETcross talk and cyclin D1 expression.Both sorafenib and SPP86 inhibited PI3K/Akt and
MAPK pathway signaling to similar degrees. Our studies
thus show that SPP86 selectively inhibits RET- induced
MCF7 cell proliferation. Additional targets of individual
kinase inhibitors with activity towards RET include the
Aurora kinases, BRAF, EGFR, JAK2, KIT, MET, p38,
PDGFRα/β and Src (Table 1). As these kinases all play
roles in regulating MCF7 proliferation and/or survival,
these inhibitors cannot be used in isolation to determine
the cellular functions of RET. Although SPP86 shows
inhibitory activity towards Src family kinases, it does not
inhibit the aforementioned kinases. Additional targets of
SPP86 such as EPHA1 and FLT4 (VEGFR3) play minor
roles in regulating MCF7 proliferation and survival
[61,62]. Its selectivity and differential target profile make
SPP86 an additional useful inhibitor for studies on RET
function in human breast cancer cell lines.Conclusions
We have demonstrated that SPP86, a novel kinase in-
hibitor, is a useful tool for studying the cellular functions
of RET. Numerous studies have identified RET as a po-
tentially important therapeutic target in subtypes of
breast, lung and thyroid cancers. Kinase inhibitors are
useful tools for studying the cellular functions of kinases.
Their relative lack of specificity can however, lead to
erroneous results. The use of two or more structurally
distinct kinase inhibitors has therefore been recom-
mended for studies on cell physiology. Our studies have
identified SPP86 as a selective inhibitor of RET signaling
in human cancer cell lines. The selectivity profile of
SPP86 is similar to that of PP1 and PP2 but differs sub-
stantially from that of other inhibitors that target RET.
Unlike PP1 and PP2 however, SPP86 does not inhibit
p38, CSK, KIT, PDGF, Src or BCR-ABL. Together, our
findings indicate that SPP86 is a useful tool for studying
the cellular functions of RET.Additional file
Additional file 1: Figure S1. Inhibition of RET phosphorylation.
(A) MCF7 cells were grown in media growing 1.0% FBS overnight,
pretreated with 2.5 μM PF573228 and/or 1 μM SPP86 for 40 min and
then exposed to 10 ng/ml of GDNF for a further 20 min in similar media.
Total lysates were resolved by SDS-PAGE and probed with antibodies
directed against phosphorylated and total Akt. Actin was used as a
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